Alec Machiels - 15 Feb 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Alec Machiels
Issuer symbol
APLS
Transactions as of
15 Feb 2022
Transactions value $
-$53,450
Form type
4
Filing time
16 Feb 2022, 15:29:06 UTC
Previous filing
19 Jan 2022
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $3,337 +1,250 +0.19% $2.67* 675,024 15 Feb 2022 Direct F1
transaction APLS Common Stock Sale -$56,787 -1,250 -0.19% $45.43 673,774 15 Feb 2022 Direct F1
holding APLS Common Stock 1,950 15 Feb 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -1,250 -0.98% $0.000000 126,029 15 Feb 2022 Common Stock 1,250 $2.67 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from 10B5-1 trading plan.
F2 Owned by spouse.
F3 This option was granted on December 5, 2013 and fully vested.